Common Variable Immunodeficiency — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Ocular manifestations of
Hwang Jodi et al. — American journal of ophthalmology case reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41778090/
- 2.
Pulmonary embolism and aseptic meningitis complicating IVIG for common variable immunodeficiency syndrome.
Butz Daniel et al. — The journal of allergy and clinical immunology. Global (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41883426/
- 3.
Immune-related enteropathy.
Butler Kimberley et al. — Current opinion in gastroenterology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41782401/
- 4.
NF-κB1 haploinsufficiency due to a novel c.104delT variant in two patients with common variable immunodeficiency.
Bylica Jan et al. — Clinical immunology (Orlando, Fla.) (30 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41921718/
- 5.
Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency.
Hayes Kevin M et al. — JCI insight (23 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41869721/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
Recruiting — Phase 2 — Monash University
https://clinicaltrials.gov/study/NCT05678621
- 2.
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Recruiting — Phase 2 — Monash University
https://clinicaltrials.gov/study/NCT07202052
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Common Variable Immunodeficiency
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
Most Recent Research
PURPOSE: To report the clinical presentation, multimodal imaging, and management in a patient with signal transducer and activator of transcription-3 (STAT3) gain-of-function (GOF) syndrome presenting with polyendocrinopathy and bilateral posterior uveitis. OBSERVATIONS: We report a case of bilateral posterior uveitis associated with STAT3-GOF syndrome. A 29-year-old female with type 1 diabetes mellitus, hypothyroidism, and common variable immune deficiency (CVID) presented with bilateral progressive decreased vision. There were no systemic signs and symptoms of infection. Clinical examination showed bilateral mild vitritis, optic disc edema with overlying telangiectasia, and mild non-proliferative diabetic retinopathy. Spectral-domain optical coherence tomography revealed parafoveal outer nuclear layer loss and cystoid macular edema bilaterally. Optic nerve leakage and diffuse capillary leakage in a fern-like pattern were visualized on fluorescein angiography. Fundus autofluorescence showed bilateral hyper-autofluorescence in the posterior poles. Laboratory and imaging workup to rule out occult infection and malignancy were unremarkable. Genetic testing for primary immunodeficiencies revealed a heterozygous germline gain-of function variant in STAT3 (STAT3 c.454C > T), confirming STAT3-GOF syndrome. The patient was treated with subcutaneous immunoglobulin and ruxolitinib, and clinical exam remained stable at 2-year follow up. CONCLUSIONS AND IMPORTANCE: STAT3-GOF syndrome may present with bilateral optic disc edema, retinitis, and retinal vascular leakage in the setting of recurrent infections and polyendocrinopathy. This case illustrates the role of monogenic mutations in non-neoplastic autoimmune retinopathy and highlights the importance of multidisciplinary management including genetic consultation for accurate diagnosis and targeted immunomodulatory treatment.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.